Skip to main content
Equibles
OPK logo

OPK · Opko Health, Inc.

Track OPK — free

Use OPK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about OPK

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.48 +0.02 (+1.37%) At close · Aug 21
Market Cap
$1.10B
Shares
746.33M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.48 Open$1.47 Day$1.46–1.52 52W close$1.10–1.65 Avg vol 30d4.1M Short int32.9M · 4.4% float · 5.4d Short vol34% Last earningsJul 27, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 27

Up next

Next earnings call
Oct 25, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 27, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 15.1 · calm Equity put/call 0.58
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +15%
      above
      Price vs 50-day avg +8%
      above
      RSI (14) 62
      neutral
      MACD trend Positive
      52-week position 69%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +21%
      trailing
      6-month return +19%
      trailing
      YTD return +17%
      this year
      Relative strength +8%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 50d above 200d
      Institutional flow Distributing
      -6% holders QoQ · +24 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.41% of float · ▼ -2.3% MoM · 5.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      223 holders — near 3-yr low, contrarian setup
      Squeeze score 60
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth −15%
      Y/Y
      Gross margin 34%
      expanding
      EPS growth −275%
      Y/Y
      Buyback $94.7M
      remaining
      Balance sheet $360.4M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 53%
      annualized · 1-yr
      Max drawdown −30%
      past year
      ATR 4.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 1 of last 2
      Latest guidance · from the Earnings Call filed Jun 30, 2024
      near-term phase of the program
      One-time costs to achieve the savings $40M
      annual
      Overall annual increase of revenue from RCM programs price incre $8M – $10M
      Prior guidance period ended · from the Earnings Call filed Jun 30, 2024
      Gross profit share payments from Pfizer · Q3 $7M – $9M
      Gross profit share payments from Pfizer · full second half of 2024 $15M – $20M
      Annualized savings · by the end of 2024 $25M
      Gain net of transaction expenses related to the closing of the L · Q3 $114M – $120M
      Costs and expenses · Q3 $153M – $156M
      Total revenues · Q3 $180M – $185M
      Revenue from services · Q3 $125M – $129M
      Revenue from the assets which will be sold to Labcorp · Q3 $24M – $25M
      Third quarter costs and expenses · Q3 $238M – $245M
      Revenue from product sales · Q3 $40M – $43M
      Other revenue · Q3 $10M – $14M
      R&D expenses · Q3 $24M – $28M
      Depreciation and amortization expense · Q3 $24M
      Guided vs delivered · last 2 settled
      Total revenues first quarter of 2024
      guided $180M – $185M
      $173.69M Miss −4.8%
      Total revenue third quarter of 2023
      guided $165M – $180M
      $178.6M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +15% Bullish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      62 Neutral
      MACD trend
      Positive Bullish
      52-week position
      69% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 50d above 200d
      Institutional flow Distributing
      -6% holders QoQ · +24 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.41% of float · ▼ -2.3% MoM · 5.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      223 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 69% Range high $2
      vs 200-day avg +15% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Cash, cash equivalents, marketable securities and restricted cash $314.4M as of June 30, 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      OPK
      Opko Health, Inc.
      this stock
      		$1.10B +17.5% -14.9% — 4.4%
      TMO
      Thermo Fisher Scientific Inc.
      		 $232.67B +8.6% +14.5% 33.6 1.3%
      DHR
      Danaher Corp /De/
      		 $151.78B -4.4% +8.5% 38.3 1.7%
      NTRA
      Natera, Inc.
      		 $47.86B +44.9% -2.8% — 3.0%
      A
      Agilent Technologies, Inc.
      		 $44.14B +16.9% +6.4% 31.4 2.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      223
      % held
      27.0%
      Net QoQ
      +404.1K sh
      Top holder
      Rubric Capital Management…
      Held Float
      View
      Held by Funds
      Fund positions
      143
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      32.9M
      Days to cover
      5.4d
      Change
      -761.1K sh
      View
      Short Volume
      Short vol %
      34%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.9K
      Value
      $3.9K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      49.3%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $606.9M
      Net income (FY)
      $-225.7M
      EPS diluted
      $-0.30
      View
      Buybacks
      Authorized
      $200.0M
      Remaining
      $94.7M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 14, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $548.0K
      Shares
      13.4K
      Filed
      Sep 20, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 27, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      OPK +7.3% +21.3% +19.4% +12.1% +17.5%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +8.6% +17.7% +7.8% +9.6% +5.2%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $200.00M
      Spent (derived)
      $105.30M
      Remaining
      $94.70M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 944809 CUSIP 68375N103 13F (30d) 196 filings 195 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)